Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3→p36.2, but absence of mutations in primary tumors

被引:28
作者
Ejeskär, K
Abel, F
Sjöberg, RM
Bäckström, J
Kogner, P
Martinsson, T [1 ]
机构
[1] Gothenburg Univ, Dept Clin Genet, Sahlgrenska Hosp E, S-41685 Gothenburg, Sweden
[2] Karolinska Hosp, Karolinska Inst, Childhood Canc Res Unit, S-10401 Stockholm, Sweden
来源
CYTOGENETICS AND CELL GENETICS | 2000年 / 89卷 / 1-2期
关键词
D O I
10.1159/000015566
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The processed product of the human gene preprocortistatin, the peptide cortistatin-17 (hCST-17), bears a strong structural resemblance to the peptide somatostatin (SST), which has an identical receptor binding domain. CST has affinity to all known SST receptor (SSTR) subtypes. Expression of both SST and its receptors has been shown in previous studies to have biological and clinical significance in neuroblastomas, with a putative role in tumor differentiation and apoptosis in vivo. In this work we have employed radiation hybrid mapping and BAC physical mapping to map the human preprocortistatin gene (CORT) to chromosome region 1p36.3 --> p36.2, close to the genetic marker D1S244. D1S244 defines the centromeric border of the smallest region of overlap of deletion in our primary neuroblastoma material. We have also defined the genomic sequence of the gene by BAC sequencing and found that preprocortistatin consists of two exons divided by a l-kb intron. Two polymorphic sites, neither of which causes amino acid exchange, have been detected in the coding region of the gene. Expression studies showed that preprocortistatin is expressed in neuroblastomas of all different stages, as well as in ganglioneuromas. Through genomic sequencing we made mutation analyses of exonic sequences in 49 primary neuroblastomas of all different stages, but no mutations could be detected. Copyright(C)2000S.KargerAG,Basel.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 21 条
[11]   A cortical neuropeptide with neuronal depressant and sleep-modulating properties [J].
deLecea, L ;
Criado, JR ;
ProsperoGarcia, O ;
Gautvik, KM ;
Schweitzer, P ;
Danielson, PE ;
Dunlop, CLM ;
Siggins, GR ;
Henriksen, SJ ;
Sutcliffe, JG .
NATURE, 1996, 381 (6579) :242-245
[12]   A comprehensive genetic map of the human genome based on 5,264 microsatellites [J].
Dib, C ;
Faure, S ;
Fizames, C ;
Samson, D ;
Drouot, N ;
Vignal, A ;
Millasseau, P ;
Marc, S ;
Hazan, J ;
Seboun, E ;
Lathrop, M ;
Gyapay, G ;
Morissette, J ;
Weissenbach, J .
NATURE, 1996, 380 (6570) :152-154
[13]   Identification and characterization of a novel human cortistatin-like peptide [J].
Fukusumi, S ;
Kitada, C ;
Takekawa, S ;
Sakamoto, J ;
Miyamoto, M ;
Hinuma, S ;
Kitano, K ;
Fujino, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 232 (01) :157-163
[14]   Somatostatin in neuroblastoma and ganglioneuroma [J].
Kogner, P ;
Borgström, P ;
Bjellerup, P ;
Schilling, FH ;
Refai, E ;
Jonsson, C ;
Dominici, C ;
Wassberg, E ;
Bihl, H ;
Jacobsson, H ;
Theodorsson, E ;
Hassan, M .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (12) :2084-2089
[15]  
MAGGI M, 1994, CANCER RES, V54, P124
[16]   Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours [J].
Martinsson, T ;
Sjöberg, RM ;
Hallstensson, K ;
Nordling, M ;
Hedborg, F ;
Kogner, P .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (12) :1997-2001
[17]  
MARTINSSON T, 1995, CANCER RES, V55, P5681
[18]   EXPRESSION OF SOMATOSTATIN RECEPTORS IN CHILDHOOD NEUROBLASTOMA [J].
MOERTEL, CL ;
REUBI, JC ;
SCHEITHAUER, BS ;
SCHAID, DJ ;
KVOLS, LK .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (06) :752-756
[19]  
ODORISIO MS, 1994, CELL GROWTH DIFFER, V5, P1
[20]  
SCHILLING FH, 1999, IN PRESS EUR J CANC